RIGL: VEPPANU launch and robust pipeline position the business for accelerated growth and profitability

A four-pillar growth strategy is driving commercial expansion, highlighted by the VEPPANU acquisition and launch, which is expected to be a major growth driver in metastatic breast cancer. The pipeline, especially R289 in MDS, is advancing with promising early results, while financial strength supp…